C. Roe et al. / Tetrahedron Letters 49 (2008) 650–653
653
transporter±; Orhan, I.; Sener, B. Acta Horticult. 2005, 678 (anticho-
linesterase activity in Alzheimer’s disease patients±.
. Pacheco, P.; Silva, M.; Steglich, W.; Watson, W. H. Rev. Latinoamer.
Quim. 1978, 9, 28–32; recent example (isolation from Pancratium
tortuosum herꢀ±: J. Pharm. Sci. 2007, 21, 61–68; structure: Zaꢀel, V.;
Watson, W. H.; Pacheco, P.; Silva, M. Cryst. Struct. Commun. 1979,
Older, J. E. J. Stephenson, G. R. unpuꢀlished results; ees up to aꢀout
40% have ꢀeen achieved with first generation chiral trityl analogues.
20. Chen, C. T.; Chao, S. D.; Yen, K. C. J. Am. Chem. Soc. 1997, 119,
11341–11342; Chen, C. T.; Chao, S. D.; Yen, K. C. Synlett 1998, 924–
926; Chen., C. T.; Chao, S. D. J. Org. Chem. 1999, 84, 1090–1091.
21. The examples reported in this Letter were performed with racemic
complexes.
8
9
8, 371–376.
. Examples of the ꢀiological activity of maritidine: Cea, G.; Alarcon,
M.; Weigart, G. Med. Sci. 1986, 14, 90 (clastogenic effect/mutagenic±;
see also Ref. 7a.
22. Malkov, A. V.; Stephenson, G. R. J. Organomet. Chem. 1995, 489,
C44–C47; see also Ref. 4.
23. For the preparation of 3,4-dimethoxyphenyllithium from 3,4-di-
methoxyꢀromoꢀenzene in THF at ꢀ78 °C, see: Meyers, A. I.; Avila,
W. B. J. Org. Chem. 1981, 46, 3881–3886; a procedure using 3,4-
dimethoxyiodoꢀenzene has also ꢀeen reported: Capparelli, M. P.;
DeSchepper, R. E.; Swenton, J. S. J. Org. Chem. 1987, 52, 4953–4957.
24. After 5 min to form the aryllithium reagent, the reaction mixture was
cooled to ꢀ78 °C ꢀefore addition of the trimethylsilyl chloride.
25. For the use of dichloromethane for the addition of organolithium
1
0. For examples, see: Nemoto, H. Chem. Pharm. Bull. 2007, 55, 961–974;
Paul, T.; Malachowski, W. P.; Lee, J. Org. Lett. 2006, 8, 4007–4010;
Taꢀer, D. F.; He, Y. J. Org. Chem. 2005, 70, 7711–7714 (mesemꢀ-
rine±; Bru, C.; Guillou, C. Tetrahedron 2006, 62, 9043–9048; Pearson,
W. H.; Lovering, F. E. J. Org. Chem. 1998, 53, 3607–3617; Martin, S.
F.; Campꢀell, C. L. J. Org. Chem. 1998, 53, 3184–3190 (crinine±; Bru,
C.; Thal, C.; Guillou, C. Org. Lett. 2003, 5, 1845–1846 (maritidine±;
For our organoiron intermediate for crinine, see Ref. 3.
5
reagents to tricarꢀonyl(g -cyclohexadienyl±iron complexes, see: Birch,
1
1. For examples of ꢀiological activities of other Amaryllidaceae alka-
loids, see: lycoramine: Han, S. Y.; Sweeney, J. E.; Bachman, E. S.;
Schweiger, E. J.; Forloni, G.; Coyle, J. T.; Davis, B. M.; Joullie, M.
M. Eur. J. Med. Chem. 1992, 27, 673–687 (against Alzheimer’s
disease±; Lopez, S.; Bastida, J.; Viladomat, F.; Codina, C. Life Sci.
A. J.; Bogs a´ nyi, D.; Kelly, L. F. J. Organomet. Chem. 1981, 214,
C39–C42.
26. Hudson, R. D. A.; Osꢀorne, S. A.; Stephenson, G. R. Tetrahedron
1997, 53, 4095–4104; Tranchier, J. P.; Chavignon, R.; Prim, D.;
Aufrant, A.; Giner Planas, J.; Rose-Munch, F.; Rose, E.; Stephenson,
G. R. Tetrahedron Lett. 2001, 42, 3311–3313.
2002, 71, 2521–2529 (inhiꢀition of acetylcholine esterase±; lycorine:
Nino, J.; Hincapie, G. M.; Correa, Y. M.; Mosquera, O. M. Zeit.
Naturforsch. C: J. Biosci. 2007, 62, 223–226 (topoisomerase inhiꢀi-
tion±; galanthamine: Weinstock, M. CNS Drugs 1999, 11, 307–323
27. Stephenson, G. R.; Owen, D. A.; Finch, H.; Swanson, S. Aust. J.
Chem. 1992, 45, 121–134; Howell, J. A. S.; Bell, A. G.; O’Leary, P. J.;
Stephenson, G. R.; Hastings, M.; Howard, P. W.; Owen, D. A.;
Whitehead, A. J.; McArdle, P.; Cunningham, D. Organometallics
1996, 15, 4247–4257; see also Ref. 3.
(treatment of Alzheimer’s disease±; Han, S. Y.; Sweeney, J. E.;
Bachman, E. S.; Schweiger, E. J.; Forloni, G.; Coyle, J. T.; Davis, B.
M.; Joullie, M. M. Eur. J. Med. Chem. 1992, 27, 673–687 (reversiꢀle
cholinesterase inhiꢀitor±.
28. Shvo, Y.; Hazum, E. Chem. Commun. 1974, 336–337; for examples in
organoiron-mediated synthesis, see: Pearson, A. J.; Ham, P.; Ong, C.
W.; Perrior, T. R.; Rees, D. C. J. Chem. Soc., Perkin Trans. 1 1982,
1527–1534; Birch, A. J.; Kelly, L. F.; Weerasuria, D. V. J. Org. Chem.
1988, 53, 278–281; Bandara, B. M. R.; Birch, A. J.; Kelly, L. F. J.
Org. Chem. 1989, 49, 4663–4763; Pearson, A. J.; O’Brien, M. K. J.
Org. Chem. 1989, 54, 4663–4673; Kn o¨ lker, H.-J.; Baum, E.; Reddy,
K. R. Tetrahedron Lett. 2000, 41, 1171–1174; Kn o¨ lker, H.-J.;
Hopfmann, T. Tetrahedron 2002, 58, 8937–8945.
1
2. Sneader, W. E. Drug Prototypes and Their Exploitation; Wiley:
Chichester, 1996.
1
2 3
3. For Guilou’s work employing the Fe(CO± Ph analogue of 3, see: (a±
Guillou, C.; Millot, N.; Reꢀoul, V.; Thal, C. Tetrahedron Lett. 1996,
5
3
7, 4515–4518; the (g -cyclohexadienyl±iron series is one of the most
widely applied of this series of electrophiles, that span the hapticity
2
7
range g –g : (ꢀ± For a survey of organoiron complexes, see:
Stephenson, G. R. Organometallic Complexes of Iron. In Science of
Synthesis; Lautens, M., Ed.; Houꢀen-Weyl Methods of Molecular
Transformations; Georg Theime Verlag: Stuttgart, 2001; Vol. 1, pp
1
29. A trace of mesemꢀrenone was also identified in the product. H NMR
spectrum of mesemꢀrenone: Jeffs, P. W.; Ahmann, G.; Campꢀell, H.
F.; Farrier, D. S.; Ganguli, G.; Hawks, R. L. J. Org. Chem. 1970, 35,
1
3
7
45–886; for earlier reviews of the applications of the cyclohexa-
dienyliron series, see: (c± Pearson, A. J. Acc. Chem. Res. 1980, 13,
63–469; (d± Pearson, A. J. Synlett 1990, 10–19; (e± Kn o¨ lker, H.-J.
Synlett 1992, 371–387; (f± Donaldson, W. A. Aldrichim. Acta 1997, 30,
7–24; (g± Kn o¨ lker, H.-J.; Braier, A.; Brocher, D. J.; Cammerer, S.;
3512–3518; for C NMR data, see: Jeffs, P. W.; Capps, T.; Johnson,
D. B.; Karle, J. M.; Martin, N. H.; Rauckman, B. J. Org. Chem. 1974,
39, 2703–2710.
4
30. For a discussion of ipso and x addition to multihapto p complexes,
see Ref. 18. For the x directing nature of aryl suꢀstituents on
cyclohexadienyliron complexes, see Ref. 3. In this case, the presence
of the 4-OMe group helps overcome the natural x selectivity and
promote the ipso pathway (ipso relative to the position of the arene±.
This is ꢀecause the C(4± OMe is also x directing (see Ref. 31±, and the
two control effects are opposed (for definitions of the terms ‘mutually
reinforcing’ and ‘opposed’ in the context of nucleophile addition to
multiply suꢀstituted ligands, see Ref. 18±.
31. For examples with opposed Me and OMe groups: Pearson, A. J.;
Perrior, T. R. J. Organomet. Chem. 1985, 285, 253–265; Pearson, A.
J.; Ham, P. J. Chem. Soc., Perkin Trans. 1 1983, 1421–1425; Pearson,
A. J.; Ham, P.; Rees, D. C. J. Chem. Soc., Perkin Trans. 1 1982, 489–
497; Tao, C.; Donaldson, W. A. J. Org. Chem. 1993, 58, 2134–2143;
We used a similar approach towards the terpene tridachione:
Stephenson, G. R. J. Chem. Soc., Perkin Trans. 1 1982, 2449–2456;
Alexander, R. P.; James, T. D.; Stephenson, G. R. J. Chem. Soc.,
Dalton Trans. 1987, 2013–2016.
1
Fr o¨ hner, W.; Gonser, P.; Hermann, H.; Herzꢀerg, D.; Reddy, K. R.;
Rohde, G. Pure Appl. Chem. 2001, 73, 1075–1086.
1
1
4. Sandoe, E. J.; Stephenson, G. R.; Swanson, S. Tetrahedron Lett. 1996,
37, 6283–6286.
5. We have developed one pot procedures to add the malononitrile
nucleophile and then perform desilylation ꢀy addition of TBAF into
the reactions mixture (conversion of 2b into 7± and for the reductive
amination of the nitrile (conversion of 7 into 8±, see Scheme 2.
6. Birch, A. J.; Cross, P. E.; Lewis, J.; White, D. A.; Wild, S. B. J. Chem.
Soc. A 1968, 332–340; see also Ref. 17.
1
1
1
7. Stephenson, G. R.; Finch, H.; Owen, D. A.; Swanson, S. Tetrahedron
1993, 49, 5649–5662.
8. For a discussion of chirality in such complexes, see: Stephenson, G. R.
In Handbook of Functionalised Organometallics; Knochel, P., Ed.;
Wiley-VCH: Weinheim, 2005; pp 569–626.
1
9. Magdziak, D.; Pettus, L. H.; Pettus, T. R. R. Org. Lett. 2001, 3, 557–
559; Older, J. E. J. PhD Thesis, University of East Anglia, 2001;
32. Roe, C.; Stephenson, G. R. Org. Lett., suꢀmitted for puꢀlication.